Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6924963 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Tracer Selection | EXPERIMENTAL | Participants will receive a single dose of one tracer on one occasion and a single dose of a different tracer after 7 to 14 days and will be followed for 7 to 14 days for safety. At the end of Part 1, one tracer with the best performance will be selected for further study in Part 2. |
| Part 2A: Test-Retest | EXPERIMENTAL | Participants will receive a single dose of selected tracer from Part 1 on one occasion and then same tracer will be administered after 6 weeks. Participants will be followed for 7 to 14 days after last PET tracer administration for safety. |
| Part 2B: Dosimetry | EXPERIMENTAL | Participants will receive a single dose of selected tracer from Part 1 and will be followed for 7 to 14 days for evaluation of radiation dosimetry. |
| Name | Type | Description |
|---|---|---|
| [11C]RO6924963 | DRUG | Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6924963 injected will be \</=10 micrograms (mcg), injection volume \</=20 milliliters (mL). Target injected activity for \[11C\]RO6924963 will be 370-740 megabecquerel (MBq) \[10-20 millicurie (mCi)\]. |
| [11C]RO6931643 | DRUG | Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6931643 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[11C\]RO6931643 will be 370-740 MBq (10-20 mCi). |
| [18F]RO6958948 | DRUG | Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[18F\]RO6958948 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of \[18F\] RO6958948 will be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection. |
Inclusion Criteria: Inclusion Criteria for All Participants * Agreement to use highly effective contraception measures * If participants are on any concomitant medication, the indication and dosage of these medicines should be stable for at least 4 weeks prior to study start with the expectation t...
RO6924963 is an investigational small molecule being studied for use in Alzheimer's Disease and in healthy volunteers. It is being evaluated as a positron emission tomography (PET) imaging tracer for tau protein, which is relevant to Alzheimer's pathology. The drug is in Phase 1 clinical development.
RO6924963 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational small molecule for potential use in Alzheimer's Disease imaging.
RO6924963 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
RO6924963 was studied in clinical trial NCT02187627, titled 'Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants.' This Phase 1 trial enrolled 52 participants in the United States and has been completed.
RO6924963 is not the same as RO6931643 or RO6958948. These are three separate investigational compounds that were evaluated together in the same clinical trial as potential PET imaging tracers for tau protein in Alzheimer's Disease and healthy volunteers.